Table 3:
Novel agents in multiple myeloma
| Agent | Class | Target | ClinicalTrials.gov Identifier | Clinical Phase | Single/Combination |
|---|---|---|---|---|---|
| ALT-801 | Protein | p53 | NCT01670994 | Phase1–2 | Single |
| TAS4464 | Small Molecule | NEDD8 | NCT02978235 | Phase1–2 | Single |
| Vemurafenib* | Small molecule | V600E BRAF mutated | NCT02693535 | Phase 2 | In combination with Cobimetinib** |
| Dabrafenib and/or Trametinib | Samll molecule | BRAF and MAPK | NCT03091257 | Phase 1 | Single agent or combined |
| AMG 176 | Small Molecule | MCL-1 | NCT02675452 | Phase 1 | Single |
| CB-5083 | Small Molecule | Cdc48p/p97 | NCT02223598 | Phase 1 | |
| CC-122 | Small Molecule | E3 ubiquitin ligase | NCT01421524 | Phase 1 | Combination with Dex |
| CPI-0610 | Small Molecule | Bromodomains | NCT02157636 | Phase 1 | Single |
| CX-4945 | Small Molecule | Protein kinase CK2/Casein Kinase II | NCT00891280, NCT01199718 | Phase 1 | Single |
| Jakafi | Small Molecule | JAK/STAT | NCT03110822 | Phase 1 | Combination with Len and methyprednisolone |
| LGH447 | Small Molecule | PIM Kinase Family | NCT02160951 | Phase 1 | Single |
| Venetoclax | Small Molecule | BCL-2 | NCT01794520 | Phase 2 | Combination with Dex |
| MIK665 | Small Molecule | MCL-1 | NCT02992483 | Phase 1 | Single |
| TG02 | Small Molecule | multi-kinase inhibitor | NCT01204164 | Phase 1 | Combination with Carfilzomib and Dex |
| Selinexor | Small Molecule | Exportin-1/CRM1/XPO1 | NCT02389543 | Phase1–2 | Combination with Len and Dex |
| Iberdomide (CC-220) | Small Molecule | Cereblon E3 ubiquitin ligase complex | NCT02773030 | Phase1–2 | Single or Combination with Dex, with Dara/Dex or Bortezomib/Dex |
| CC-92480 | Small molecule | Cereblon E3 ubiquitin ligase complex | NCT03374085 | Phase 1 | Combination with Dex |
| ONC201 | Small Molecule | Dopamine 2 (D2) Receptor | NCT02863991 | Phase1–2 | Single |
| Oprozomib | Small Molecule | Proteasome | NCT01832727 | Phase1–2 | Combination with Dex |
| PT-112 | Small Molecule | Apoptosis | NCT03288480 | Phase1–2 | Single |
| Ricolinostat | Small Molecule | Histone Deacetylase | NCT01997840 | Phase1–2 | Combination with Pom/Dex |
| EDO-S101 | Small Molecule | Histone Deacetylase DNA | NCT02576496 | Phase | Single |
| LCL161 | Small Molecule | Apoptosis proteins) | NCT01955434 | Phase 2 | Single or in combination with cyclophosphamide |
| CLR 131 | Small Molecule | Radio-pharmaceutical | NCT02952508 | Phase 2 | Single |
| Filanesib | Small molecule | kinesin spindle protein | NCT01372540 | Phase 1 | Combination with carfilzomib |
| Afuresertib | Small molecule | AKT | NCT02235740 | Phase 1 | Combination with carfilzomib |
| Pelareorep | Viral | Oncolytic Virus | NCT00450814 | Phase1–2 | Single or in combination with cyclophosphamide |
| Melflufen | Melphalanderivative | DNA | NCT02963493 | Phase 2 | Combination with Dex |
Novel agents in multiple myeloma and stage of ongoing clinical trials (Mab= monoclonal antibody, Mab-bi=monoclonal antibody bispecific, Dex=dexamethasone, Len= lenalidomide, Pom=pomalidomide, * this trial is also evaluating 14 other targeted therapies and Vemurafenib is combined with cobimetinib (MEK1 inhibitor))